April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Distribution of Risk Factors in Newly Diagnosed Ocular Hypertension and Open-Angle Glaucoma Patients in Canada
Author Affiliations & Notes
  • Y. M. Buys
    Department of Ophthalmology & Vision Sci, University of Toronto, Toronto, Ontario, Canada
  • P. Harasymowycz
    Institut de glaucome de Montreal, Montreal, Quebec, Canada
  • R. Gaspo
    Pfizer Canada Inc., Kirkland, Quebec, Canada
  • K. Kwok
    Pfizer Inc., New York, New York
  • T. Nguyen
    Pfizer Canada Inc., Kirkland, Quebec, Canada
  • D. Zhou
    Pfizer Inc., New York, New York
  • Canadian Glaucoma Risk Factor Study Group
    Department of Ophthalmology & Vision Sci, University of Toronto, Toronto, Ontario, Canada
  • Footnotes
    Commercial Relationships  Y.M. Buys, Pfizer Canada, F; P. Harasymowycz, Pfizer Canada, F; R. Gaspo, Pfizer Canada, E; K. Kwok, Pfizer Inc., E; T. Nguyen, Pfizer Canada, E; D. Zhou, Pfizer Inc., E.
  • Footnotes
    Support  Pfizer Canada Inc.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 3975. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y. M. Buys, P. Harasymowycz, R. Gaspo, K. Kwok, T. Nguyen, D. Zhou, Canadian Glaucoma Risk Factor Study Group; Distribution of Risk Factors in Newly Diagnosed Ocular Hypertension and Open-Angle Glaucoma Patients in Canada. Invest. Ophthalmol. Vis. Sci. 2010;51(13):3975.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Understanding risk factors in relation to disease is important for both diagnosis and treatment. In glaucoma, several risk factors have been identified however the literature is at times conflicting, suggesting further study of this topic to be of value. This study was designed to describe the presence and distribution of risk factors in Canadian patients with newly diagnosed ocular hypertension (OH) and open-angle glaucoma (OAG).

Methods: : Subjects with newly diagnosed OH or OAG and not receiving ocular hypotensive therapy were enrolled following informed consent. Subjects underwent a complete medical history and ocular examination with results recorded on standardized data collection sheets. Descriptive statistics of all variables for the two diseases (OH and OAG) were calculated. In order to assess which risk factors and/or ocular variables were associated with OAG versus OH, adjusted odds ratios (OR), along with 95% confidence intervals (CIs), were obtained from multiple logistic regression models.

Results: : 405 subjects were included, 292 (72.1%) with OAG (202 primary, 65 normal tension, 16 pseudoexfoliation, 9 pigmentary glaucoma) and 113 (27.9%) with OH. The majority of subjects were Caucasian (348/405; 85.9%). The results of multiple logistic regression found that the odds ratio for OAG compared to OH was 8.19 (95% CI: 2.93-22.88; p<0.0001) for optic disc notch, 5.36 (95% CI: 2.12-13.56; p<0.001) for abnormal VF, 1.45 (95% CI: 1.17-1.80; p=0.001) for every one dB unit worsening of mean deviation, 1.91 (95% CI: 1.54-2.37; p<0.0001) for every 0.1 unit increase of cup-to-disc ratio, 1.03 for increased yearly age (95% CI:1.00-1.06; p=0.030), 0.36 (95% CI: 0.17-0.78; p=0.010) for smoking, and 0.27 (95% CI: 0.11,0.63; p=0.003) for location (Quebec/Atlantic vs Ontario).

Conclusions: : The OAG subjects were more likely to have abnormal optic disc features and VF indices. Increased age was a risk for OAG when compared to OH whereas in this study, smoking and living in Quebec or Atlantic Canada compared to Ontario decreased the risk of OAG when compared to OH.

Keywords: clinical (human) or epidemiologic studies: risk factor assessment • clinical (human) or epidemiologic studies: health care delivery/economics/manpower • clinical (human) or epidemiologic studies: biostatistics/epidemiology methodology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×